Journal scan

Stereotactic body radiotherapy beneficial for COPD patients with localised NSCLC

Lung cancer radiotherapy

Non-small cell lung cancer (NSCLC) is a cause of considerable mortality and morbidity but, for patients staged T1-2N0M0, surgical resection can be curative.

Unfortunately, surgical operability and success are often compromised by the presence of co-existing conditions. Chronic obstructive pulmonary disease (COPD) and NSCLC are often co-morbid diseases with up to 70% of patients experiencing both conditions associated with poor prognoses.

The aim of this Danish study was to compare survival in COPD patients with localised NSCLC who were treated with stereotactic body radiotherapy (the NSCLC group), with COPD patients without a diagnosis of cancer (the non-malignant control group).

Data from 102 NSCLC patients were collected prospectively; data from 572 suitable non-malignant patients were collected retrospectively from a review of medical records. The primary endpoint of the evaluation was overall survival.

Higher mortality

...

Non-small cell lung cancer (NSCLC) is a cause of considerable mortality and morbidity but, for patients staged T1-2N0M0, surgical resection can be curative.

Lung cancer radiotherapy
Lung cancer radiotherapy. Picture: Science Photo Library

Unfortunately, surgical operability and success are often compromised by the presence of co-existing conditions. Chronic obstructive pulmonary disease (COPD) and NSCLC are often co-morbid diseases with up to 70% of patients experiencing both conditions associated with poor prognoses.

The aim of this Danish study was to compare survival in COPD patients with localised NSCLC who were treated with stereotactic body radiotherapy (the NSCLC group), with COPD patients without a diagnosis of cancer (the non-malignant control group).

Data from 102 NSCLC patients were collected prospectively; data from 572 suitable non-malignant patients were collected retrospectively from a review of medical records. The primary endpoint of the evaluation was overall survival.

Higher mortality rates

The median overall survival was 53 versus 71 months in the NSCLC and non-malignant groups respectively. There was a statistically significant higher mortality rate for patients with mild to moderate COPD and a diagnosis of localised NSCLC.

For those patients not eligible for surgery, the authors of this study suggest stereotactic body radiotherapy has developed and demonstrated itself to be a curative treatment modality, which should be considered beneficial even for COPD patients with localised NSCLC.


Jeppesen S, Hansen N, Schytte T et al (2016) Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer. Lung Cancer. 100, 90-95.

Want to read more?

Subscribe for unlimited access

Enjoy 1 month's access for £1 and get:

  • Full access to cancernursingpractice.com
  • Bi-monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal

This article is not available as part of an institutional subscription. Why is this?

Jobs